Researchers investigated the role of components of the Hippo signaling pathway for E-cadherin-mediated contact inhibition of proliferation in the lungs after air pollution exposure.
The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19.
Allergen sensitization to five common indoor allergens was assessed in former smokers with COPD. Home settled dust was assessed for presence of corresponding allergens.
[American Journal of Respiratory and Critical Care Medicine]
Researchers investigated the role of lysocardiolipin acyltransferase expression and activity in mitochondrial oxidative stress, mitochondrial dynamics, and lung epithelial cell apoptosis.
Peripheral blood endothelial progenitor cells were isolated from nonsmoking non-chronic obstructive pulmonary disease (COPD), smoking non-COPD, and smoking COPD patients. The expressions of p16, p300, and senescence-related genes were detected by RT-PCR and Western Blot.
Scientists confirmed that EPAS1-specific inhibitor PT2385 ameliorated HPH features, as demonstrated by right ventricle hypertrophy, right ventricular systolic pressure, and pulmonary vascular remodeling.
Allogeneic, bone marrow-derived MSCs were systemically administered into patients with stable chronic obstructive pulmonary disease. Gene expression profiles from peripheral blood mononuclear cells were analyzed across the first week after infusion.
The effects of the RAGE ligands LL-37 and HMGB1 were examined on airway inflammation and alveolar tissue damage in wild-type and RAGE deficient mice and on lung damage and repair responses using murine precision cut lung slices and organoids.
[American Journal of Physiology-Lung Cellular and Molecular Physiology]
EpiEndo Pharmaceuticals, Inc. announced the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council (EIC) Fund joining the round. The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
